Keri P. Mattox now holds the newly created position of Senior Vice President, Investor Relations and Chief Communications Officer at Warsaw, Indiana-based Zimmer Biomet Holdings, Inc. She brings to the table more than 20 years in investor relations and communications across multiple industries. In this new role, says the company, Mattox will be responsible for, “strategically integrating, aligning and driving investor relations, communications and philanthropy functions and activities.”
Keri P. Mattox: New Senior VP, Investor Relations and CCO
1 min read Premium comments
#zimmerbiometSecondary#kerimattox
Although retiring as Senior Vice President of Investor Relations, Coleman Lannum will stay on board and work with Mattox during a transition period.
Mattox was most recently at W2O Group, an international healthcare-focused marketing and communications firm, where she served as Global Lead, Integrated Corporate Communications and formulated and expanded the company’s corporate communications, investor relations, crisis communications, board engagement and corporate social responsibility/foundation issues.
“Keri brings deep expertise and a history of successfully driving effective investor relations, communications and corporate social responsibility programs,” said Suky Upadhyay, Zimmer Biomet CFO. “Her proven track record of integrating investor relations and communications strategies will be critical as we continue to focus on transforming our business.”
According to Zimmer Biomet, “Prior to W2O, Mattox was Vice President, Corporate & Investor Relations at AmerisourceBergen, a healthcare company ranked #10 on the Fortune 500 in 2019 with nearly $170 billion in annual revenue. She also held executive leadership level positions at Endo International and Auxilium Pharmaceuticals and spent more than 10 years at communications agencies in leadership positions.”
Keri Mattox told OTW, “I’m pleased to be joining Zimmer Biomet at such an exciting time for the Company. The integration of our Investor Relations, Communications and Philanthropy functions is the next important step in the Company’s cultural transformation to one Zimmer Biomet. I look forward to further sharing Zimmer Biomet’s innovative strategy and vision with all of our internal and external stakeholders.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.